Replies to post #154403 on Biotech Values

[dav1234]

FOLD -50% a/h.. Amicus Therapeutics (FOLD) and GlaxoSmithKline (GSK) announce results from the Phase III study of its investigational oral migalastat HCl monotherapy in patients with Fabry disease, noting the pre-designated primary endpoint was not achieved. FOLD -50%, GSK -0.7% AH

[jq1234]

Where is my credit :-)? Genisi actually became less pessimistic (or more optimistic) later on :-). Unfortunately Amigal monotherapy in Fabry is their main value IMO. I still maintain there isn't that much value for combination with ERT.